Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Taking a polypill for heart failure, according to research, may have real benefits. But, like all conventional medications, there are strengths and weaknesses, pros and cons for anyone considering this therapy.
I am a myeloma survivor who developed chemotherapy-induced cardiomyopathy and atrial fibrillation as a long-term side effect of my cardiotoxic chemo regimens. At this point in my cancer survival, I am more likely to die of one of my treatment-induced side effects than I am of my original cancer.
Heart failure is right at the top of this list of possible causes of death.
As such, I have researched and have developed a number of heart-healthy evidence-based therapies that have either stabilized or improved my heart metrics.
Evidence-based heart healthy therapies include:
But I am the first person to admit that there are many people in this world who are either at-risk for HF or already exhibit different heart problems who would benefit from a polypill.
To put this sentiment differently, I admit that I have the incentive to pursue the non-conventional therapies above (cancer survivor with a number of long-term side effects) as well as the time (I am an empty nester) so I may be sort of an outlier in this regard.
Therefore, for someone who is “at risk” of heart failure, taking one single pill that contains
could reduce your risk of stroke, reduce your cholesterol, reduce your BP, etc. all with one pill. Hopefully the medication is covered by your insurance and does not cause you any side effects.
Pros:
Cons:
“Interventions to promote healthy lifestyles and simplify pharmacotherapy regimens are available, however, implementation of the concepts remain challenging. Historically, this has been driven by:
As such, the notion of a fixed-drug combination in one pill – “the polypill” – represents a potential strategy to enhance cardiovascular prevention efforts at a population level.2 Traditionally, polypills combine lipid and blood pressure lowering therapy (with or without aspirin) and have been tested in low/middle income populations at increased risk of cardiovascular disease3 (CVD) (Table 1)…
Conclusion- Fixed-dose combination therapy (polypill) with or without aspirin is associated with greater reductions in cardiovascular risk factors and major cardiovascular events when compared to usual care, placebo, or active comparators.
These benefits are offset, to some degree, by the fact that polypills may not be well tolerated in some individuals. Barriers to polypill implementation may be overcome with a hybrid approach, marrying population-based and risk-based strategies (with the addition of imaging) for the prevention of CVD.”